Cullinan Oncology Company Leadership
| CGEM Stock | USD 23.46 0.52 2.17% |
Cullinan Oncology's insiders are aggressively selling. The analysis of the overall insider sentiment regarding Cullinan Oncology LLC suggests that most insiders are panicking. Cullinan Oncology employs about 85 people. The company is managed by 11 executives with a total tenure of roughly 199 years, averaging almost 18.0 years of service per executive, having 7.73 employees per reported executive.
Cullinan Oncology's Insider Buying Vs Selling
0
Selling | Buying |
Latest Trades
| 2024-05-06 | Jennifer Michaelson | Disposed 58000 @ 28.07 | View | ||
| 2024-02-01 | Corrine Savill | Disposed 40000 @ 16.18 | View | ||
| 2024-01-29 | Corrine Savill | Disposed 40000 @ 14.09 | View | ||
| 2024-01-22 | Corrine Savill | Disposed 18684 @ 12.14 | View | ||
| 2023-12-26 | Nadim Ahmed | Disposed 4272 @ 9.24 | View | ||
| 2023-12-21 | Jeffrey Trigilio | Disposed 1920 @ 8.5 | View | ||
| 2023-12-18 | Jeffrey Trigilio | Disposed 398 @ 8.22 | View | ||
| 2023-12-12 | Jennifer Michaelson | Disposed 1068 @ 7.81 | View | ||
| 2023-06-28 | Nadim Ahmed | Disposed 759 @ 11.4 | View | ||
| 2023-06-20 | Jeffrey Trigilio | Disposed 399 @ 12.94 | View | ||
| 2023-06-12 | Jennifer Michaelson | Disposed 176 @ 13.11 | View | ||
| 2023-06-06 | Jennifer Michaelson | Disposed 11900 @ 12.31 | View | ||
| 2023-05-23 | Nadim Ahmed | Disposed 707 @ 9.15 | View |
Monitoring Cullinan Oncology's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Cullinan |
Cullinan Oncology Management Team Effectiveness
The company has return on total asset (ROA) of (0.2215) % which means that it has lost $0.2215 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2947) %, meaning that it created substantial loss on money invested by shareholders. Cullinan Oncology's management efficiency ratios could be used to measure how well Cullinan Oncology manages its routine affairs as well as how well it operates its assets and liabilities. As of the 21st of May 2024, Return On Tangible Assets is likely to grow to -0.3. In addition to that, Return On Capital Employed is likely to grow to -0.4. At this time, Cullinan Oncology's Total Assets are very stable compared to the past year. As of the 21st of May 2024, Other Current Assets is likely to grow to about 13.8 M, while Non Current Assets Total are likely to drop about 4.7 M.As of the 21st of May 2024, Common Stock Shares Outstanding is likely to grow to about 42.3 M. Also, Net Income Applicable To Common Shares is likely to grow to about 134.3 M
Cullinan Oncology Workforce Comparison
Cullinan Oncology LLC is rated below average in number of employees category among related companies. The total workforce of Health Care industry is currently estimated at about 3,129. Cullinan Oncology holds roughly 85.0 in number of employees claiming about 2.72% of equities under Health Care industry.
Cullinan Oncology Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Cullinan Oncology insiders, such as employees or executives, is commonly permitted as long as it does not rely on Cullinan Oncology's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Cullinan Oncology insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2024-06-01 | 0.8 | 4 | 5 | 271,224 | 119,212 |
| 2024-03-01 | 1.0 | 16 | 16 | 1,345,875 | 426,875 |
| 2023-06-01 | 0.28 | 7 | 25 | 88,140 | 31,667 |
| 2023-03-01 | 2.125 | 17 | 8 | 1,713,500 | 6,402,038 |
| 2022-12-01 | 1.5 | 3 | 2 | 30,351 | 8,000 |
| 2022-09-01 | 0.2222 | 2 | 9 | 198,000 | 94,967 |
| 2022-06-01 | 1.3333 | 16 | 12 | 701,267 | 720,919 |
| 2022-03-01 | 15.0 | 15 | 1 | 991,880 | 1,187,734 |
| 2021-12-01 | 0.25 | 3 | 12 | 2,722,000 | 133,477 |
| 2021-09-01 | 0.1264 | 11 | 87 | 88,000 | 814,073 |
| 2021-03-01 | 0.9024 | 37 | 41 | 31,475,440 | 48,023,612 |
Cullinan Oncology Notable Stakeholders
A Cullinan Oncology stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Cullinan Oncology often face trade-offs trying to please all of them. Cullinan Oncology's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Cullinan Oncology's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Patrick Baeuerle | Chief CoFounder | Profile | |
| Nadim Ahmed | CEO President | Profile | |
| Jennifer Michaelson | Chief Officer | Profile | |
| Kerry Whalen | Director Devel | Profile | |
| Jeffrey Trigilio | CFO Treasurer | Profile | |
| Steve Andre | Chief Officer | Profile | |
| Kevin Johnston | Chief Officer | Profile | |
| Corinne Savill | Chief Officer | Profile | |
| Rose Weldon | Senior Communications | Profile | |
| Jacquelyn JD | Chief Officer | Profile | |
| MBA MD | Chief Officer | Profile |
About Cullinan Oncology Management Performance
The success or failure of an entity such as Cullinan Oncology LLC often depends on how effective the management is. Cullinan Oncology management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Cullinan management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Cullinan management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.32) | (0.30) | |
| Return On Capital Employed | (0.42) | (0.40) | |
| Return On Assets | (0.32) | (0.30) | |
| Return On Equity | (0.34) | (0.32) |
The data published in Cullinan Oncology's official financial statements usually reflect Cullinan Oncology's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Cullinan Oncology LLC. For example, before you start analyzing numbers published by Cullinan accountants, it's critical to develop an understanding of what Cullinan Oncology's liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Cullinan Oncology's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Cullinan Oncology's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Cullinan Oncology's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Cullinan Oncology LLC. Please utilize our Beneish M Score to check the likelihood of Cullinan Oncology's management manipulating its earnings.
Cullinan Oncology Workforce Analysis
Traditionally, organizations such as Cullinan Oncology use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Cullinan Oncology within its industry.Cullinan Oncology Manpower Efficiency
Return on Cullinan Oncology Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 1.8M | |
| Net Loss Per Executive | 13.9M | |
| Working Capital Per Employee | 5.3M | |
| Working Capital Per Executive | 41.1M |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cullinan Oncology LLC. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in income. Note that the Cullinan Oncology LLC information on this page should be used as a complementary analysis to other Cullinan Oncology's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Complementary Tools for Cullinan Stock analysis
When running Cullinan Oncology's price analysis, check to measure Cullinan Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cullinan Oncology is operating at the current time. Most of Cullinan Oncology's value examination focuses on studying past and present price action to predict the probability of Cullinan Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cullinan Oncology's price. Additionally, you may evaluate how the addition of Cullinan Oncology to your portfolios can decrease your overall portfolio volatility.
| Stocks Directory Find actively traded stocks across global markets | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges |
Is Cullinan Oncology's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cullinan Oncology. If investors know Cullinan will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cullinan Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.13) | Return On Assets (0.22) | Return On Equity (0.29) |
The market value of Cullinan Oncology LLC is measured differently than its book value, which is the value of Cullinan that is recorded on the company's balance sheet. Investors also form their own opinion of Cullinan Oncology's value that differs from its market value or its book value, called intrinsic value, which is Cullinan Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cullinan Oncology's market value can be influenced by many factors that don't directly affect Cullinan Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cullinan Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cullinan Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cullinan Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.